Truist lowered the firm’s price target on Globus Medical (GMED) to $68 from $80 and keeps a Hold rating on the shares. The firm cites the company’s surprising Q1 earnings and revenue miss, noting that while distributor and supply chain items should prove somewhat transitory, the weaker capital sales from elongating robot deals is a bit more concerning, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED: